Valuation by Technicalbuy
in response to
by
development & production
Commercialization of protein-based vaccines & biopharmaceuticals
Message: Another positive NR out today.
Your Vote:
Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
"Medicago announced on August 20 that they signed an MOU with Ajanta Pharma to bring their VLP technology to India (and other areas). This deal, which should be finalized within the next 90 days, is a huge coup for a small company like Medicago. Ajanta is the Indian biotech darling with fast growth and strong ties to government, defense and health care in India. India itself is one of the biggest markets in the world with over 1 Billion people and growing in numbers and wealth.
So let’s do the new math...again with all the assumptions made in the last letter.
Quebec Plant - 30 million doses/yr
France Plant - 30 million doses/yr
India Plant - 30 million doses/yr
Now remember they all can be expanded easily and this assumes that France and India will build similar plants when in reality they will likely be state of the art and larger.
90 million doses * $5/dose = $450 Million/yr in revenue from these 3 plants (again remember most vaccines are now selling for $7- $10 but we are not sure of the structure of the licensing deal)
With 10X Earnings and the low cost of production that's a potential valuation of $4.5 Billion for Medicago."
3 Recommendations
Loading...
Loading...
New Message
Please
login
to post a reply